Rhumbline Advisers Buys 5,833 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Rhumbline Advisers lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 410,508 shares of the biopharmaceutical company's stock after purchasing an additional 5,833 shares during the quarter. Rhumbline Advisers owned about 0.32% of Halozyme Therapeutics worth $19,626,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vontobel Holding Ltd. purchased a new position in Halozyme Therapeutics during the fourth quarter valued at $377,000. Castellan Group raised its position in shares of Halozyme Therapeutics by 2.3% in the 4th quarter. Castellan Group now owns 116,470 shares of the biopharmaceutical company's stock worth $5,568,000 after purchasing an additional 2,672 shares during the last quarter. Davidson Capital Management Inc. boosted its stake in Halozyme Therapeutics by 111.2% in the 4th quarter. Davidson Capital Management Inc. now owns 56,639 shares of the biopharmaceutical company's stock worth $2,708,000 after purchasing an additional 29,826 shares in the last quarter. Louisiana State Employees Retirement System grew its position in Halozyme Therapeutics by 0.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock valued at $1,688,000 after purchasing an additional 200 shares during the last quarter. Finally, Shaker Investments LLC OH increased its stake in Halozyme Therapeutics by 12.3% during the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock valued at $3,601,000 after purchasing an additional 8,249 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

HALO traded up $0.31 during trading on Friday, hitting $57.75. The company's stock had a trading volume of 1,299,523 shares, compared to its average volume of 1,313,186. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm has a market cap of $7.11 billion, a PE ratio of 16.84, a P/E/G ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $65.53. The business's 50 day simple moving average is $53.46 and its 200-day simple moving average is $54.62.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.72 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 43,611 shares of the company's stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on HALO. JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a report on Friday, November 1st. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. HC Wainwright increased their price objective on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday. Benchmark reiterated a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday. Finally, Wells Fargo & Company dropped their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.